Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 11:18:181-205.
doi: 10.1146/annurev-bioeng-110315-020137. Epub 2016 Feb 24.

Immune Tolerance for Autoimmune Disease and Cell Transplantation

Xunrong Luo  1   2 , Stephen D Miller  3 , Lonnie D Shea  4
Affiliations
Review

Immune Tolerance for Autoimmune Disease and Cell Transplantation

Xunrong Luo et al. Annu Rev Biomed Eng. .

Abstract

The undesired destruction of healthy cells, either endogenous or transplanted, by the immune system results in the loss of tissue function or limits strategies to restore tissue function. Current therapies typically involve nonspecific immunosuppression that may prevent the appropriate response to an antigen, thereby decreasing humoral immunity and increasing the risks of patient susceptibility to opportunistic infections, viral reactivation, and neoplasia. The induction of antigen-specific immunological tolerance to block undesired immune responses to self- or allogeneic antigens, while maintaining the integrity of the remaining immune system, has the potential to transform the current treatment of autoimmune disease and serve as a key enabling technology for therapies based on cell transplantation.

Keywords: cell therapies; immunomodulation; inverse vaccines; nanotechnology; tolerance.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE STATEMENT

S.D.M. and L.D.S. have a financial interest in Cour Pharmaceuticals.

Figures

Figure 1
Figure 1
Tolerance by antigen (Ag) presentation without costimulation. Antigens are internalized by antigen-presenting cells (APCs), and after processing, a peptide of 7–10 amino acids or 14–20 amino acids can be presented on major histocompatibility complex (MHC) I or II, respectively, for recognition by the T cell receptor (TCR) on T cell subsets. The plasticity of T cell subsets enables their response resulting in either immunity or the induction of tolerance. (a) Immunity. The T cell clones mediating the undesired response contain a TCR that recognizes the Ag presented by an APC presenting the MHC/Ag complex (signal 1). The interaction between costimulatory factors present on APCs and cognate receptors on T cells is also needed to cause T cell activation (signal 2). The final stage of T cell activation involves the interaction of soluble mediators (such as interleukins or other factors) with receptors on the T cell surface (signal 3). (b) Blockade of the positive costimulatory CD28/B7 signaling axis between T cells and APCs by the cytotoxic T lymphocyte antigen 4 (CTLA-4)–Ig fusion protein serves as a constitutive regulatory control switch, and it has been exploited as a tolerogenic regimen for autoimmunity treatment. Programmed death 1 (PD-1) signaling on T cells by its ligands PD-L1 and PD-L2 represents another regulatory mechanism of immune responses, and it has been extensively studied in the context of autoimmunity and T cell exhaustion and deletion. Selective blockade of the PD-1/PD-L1 signaling axis can disrupt tolerance induction by blocking T cell receptor stop signals, thereby decreasing T cell motility and increasing physical interactions with APCs, resulting in enhanced immune responses. (c) Induction of regulatory T cells (Tregs) as a mechanism to achieve Ag-specific immunoregulation. In the presence of transforming growth factor β (TGF-β) and interleukin-2 (IL-2), naïve T cells can be differentiated into Tregs that release immunosuppressive cytokines such as IL-10 to diminish the induction and proliferation of effector T cells.
Figure 2
Figure 2
Schematic illustrating tolerogenic approaches being developed for delivery (a) subcutaneously, (b) to the lymphatics, or (c) intravenously. Factors delivered subcutaneously can release factor locally, be internalized by cells within the subcutaneous space, or travel to the lymphatics. Intravenous delivery can involve soluble antigen (Ag) or modified Ag or nanoparticles that can associate with cells in the blood, or it can be internalized by antigen-presenting cells in organs such as the liver or spleen. Abbreviation: Ag-SP, antigen coupled to splenocytes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Miller SD, Turley DM, Podojil JR. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol. 2007;7:665–77. - PubMed
    1. Zakrzewski JL, van den Brink MR, Hubbell JA. Overcoming immunological barriers in regenerative medicine. Nat Biotechnol. 2014;32:786–94. - PMC - PubMed
    1. Tobias LD. A Briefing Report on Autoimmune Diseases and AARDA: Past, Present, and Future. Eastpointe, MI: AARDA; 2010.
    1. Fischbach MA, Bluestone JA, Lim WA. Cell-based therapeutics: the next pillar of medicine. Sci Transl Med. 2013;5:179ps7. - PMC - PubMed
    1. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230–38. - PubMed